world-biomarkers-pharma-biotech-2017-posters

23 / 61

Notes:
Volume10, Issue 12 (Suppl) J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 79
conferenceseries.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20th International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9th WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
Cardiac troponins and their predictive value of myocardial injury on model of chronic anthracycline
cardiomyopathy
Michaela Adamcova
Charles University in Hradec Králové, Czech Republic
C ardiac troponins (cTn) seem to be more sensitive for the detection of anthracycline cardiotoxicity than the currently
recommended method of monitoring LV systolic function. However, the optimal timing of blood sampling remains
unknown. Hence, the aims of the present study were to determine the diagnostic window for cTns during the development
of chronic anthracycline cardiotoxicity and to evaluate their predictive value. Cardiotoxicity was induced in rabbits with
daunorubicin (3 mg/kg, weekly, for 8 weeks). Blood samples were collected 2-168 hrs after 1st, 5th and 8th drug administration,
and concentrations of cTns were determined using highly sensitive assays: hs cTnT (Roche) and hs cTnI (Abbott). The plasma
levels of cTns progressively increased with the rising number of chemotherapy cycles. While only amild non-significant increase
in both cTn levels occurred after the 1st daunorubicin dose, a significant rise was observed after the 5th and 8th administrations.
Two hours after these administrations, a significant increase occurred with a peak between 4-6 hrs and a decline until 24 hrs.
While greater variability of cTn levels was observed around the peak concentrations, the values did not correspond well with
the severity of LV systolic dysfunction. Unlike AMI in cardiotoxicity, cTn elevations may be better associated with cumulative
dose and AUC than cmax. Very strong correlation between dP/dtmax and AUCtotal5-10 (calculated from the 5th till the 10th
week) for both cTnI and cTnT (R=-0.857, p<0.01 and R=-0.833, p<0.01; respectively) and LV FS (R=-0.810, p<0.01 and R=-
0.833, p<0.01; respectively) were found.
Biography
Michaela Adamcova is an expert in cardiovascular toxicity markers. Her research activities have been focused mainly on cardiac troponins as translational markers
for evaluation of cardiotoxic and potentially cardioprotective effects of new drugs in oncology. She has published 84 scientific papers, including several invited
reviews, e.g. “Troponin as a marker of myocardial damage in drug-induced cardiotoxicity” for the journal Expert Opinion on Drug Safety, commentary “Troponins in
children and neonates” for Acta Paediatrica and “Cardiac troponins – translational biomarkers in cardiology: Theory and practice of cardiac troponin high assays”
for BioFactors.
Michaela Adamcova, J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-110